0,1
4.1.4.2.2.2 Summary of evidence and recommendation for Beta-3 agonists,
Summary of evidence,LE
Mirabegron and vibegron are better than placebo for improvement of OAB/UUI symptoms.,1a
Adverse event rates with mirabegron and vibegron are similar to those of placebo.,1a
"Beta-3 agonists are as effective as antimuscarinics in the management of OAB but with lower dry 
mouth rates.",1a
"Patients inadequately treated with solifenacin 5 mg may benefit more from the addition of mirabegron 
rather than dose escalation of solifenacin.",1b
Recommendations,Strength rating
"Offer beta-3 agonists as an alternative to anticholinergics to women with OAB who fail 
conservative treatment.",Strong
"Offer mirabegron as an additional therapy in patients who are inadequately treated with 
solifenacin 5 mg.",Weak
